Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2022-02-02
2023-08-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia
NCT02298933
Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness
NCT06254560
The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias
NCT00472433
Platelet Reactivity In Patients With Nuisance Bleeding On A Thienopyridine
NCT01152229
The Association Between Platelet Reactivity and Bleeding Risk in Adult ITP
NCT03377439
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with Platelet Transfusion Refractoriness
platelet transfusion
platelet transfusion realised for Hematopoietic stem cells graft or for acute leukemia
Patients without Platelet Transfusion Refractoriness
platelet transfusion
platelet transfusion realised for Hematopoietic stem cells graft or for acute leukemia
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
platelet transfusion
platelet transfusion realised for Hematopoietic stem cells graft or for acute leukemia
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Minor patient
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut de cancérologie Strasbourg Europe
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Luc FORNECKER
Role: PRINCIPAL_INVESTIGATOR
Institut de cancérologie Strasbourg Europe
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institut de cancérologie Strasbourg Europe
Strasbourg, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.